Hainan Haiyao Co., Ltd.

SZSE:000566 Voorraadrapport

Marktkapitalisatie: CN¥6.3b

Hainan Haiyao Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Hainan Haiyao has been growing earnings at an average annual rate of 8.1%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been declining at an average rate of 12.6% per year.

Belangrijke informatie

8.1%

Groei van de winst

8.1%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie10.9%
Inkomstengroei-12.6%
Rendement op eigen vermogen-20.6%
Nettomarge-36.6%
Laatste winstupdate30 Sep 2024

Recente prestatie-updates uit het verleden

Recent updates

What Hainan Haiyao Co., Ltd.'s (SZSE:000566) 31% Share Price Gain Is Not Telling You

Oct 25
What Hainan Haiyao Co., Ltd.'s (SZSE:000566) 31% Share Price Gain Is Not Telling You

Hainan Haiyao (SZSE:000566) Is Carrying A Fair Bit Of Debt

Oct 06
Hainan Haiyao (SZSE:000566) Is Carrying A Fair Bit Of Debt

Revenues Not Telling The Story For Hainan Haiyao Co., Ltd. (SZSE:000566)

Sep 09
Revenues Not Telling The Story For Hainan Haiyao Co., Ltd. (SZSE:000566)

Hainan Haiyao Co., Ltd.'s (SZSE:000566) Shares May Have Run Too Fast Too Soon

Jun 07
Hainan Haiyao Co., Ltd.'s (SZSE:000566) Shares May Have Run Too Fast Too Soon

Investor Optimism Abounds Hainan Haiyao Co., Ltd. (SZSE:000566) But Growth Is Lacking

Feb 26
Investor Optimism Abounds Hainan Haiyao Co., Ltd. (SZSE:000566) But Growth Is Lacking

Opbrengsten en kosten

Hoe Hainan Haiyao geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

SZSE:000566 Opbrengsten, kosten en inkomsten (CNY Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Sep 241,031-37741471
30 Jun 241,112-31639959
31 Mar 241,347-12745163
31 Dec 231,479-10649455
30 Sep 231,5575375049
30 Jun 231,6733980354
31 Mar 231,7203377550
01 Jan 231,7791182549
30 Sep 222,034-1,1261,107187
30 Jun 222,094-1,1971,187192
31 Mar 222,067-1,4221,297197
01 Jan 222,059-1,5551,304197
30 Sep 212,038-1,0971,444132
30 Jun 212,157-1,0111,480131
31 Mar 212,243-6301,404129
31 Dec 202,200-5801,456126
30 Sep 202,173-2631,439124
30 Jun 202,111-1871,402107
31 Mar 202,192-3341,557102
31 Dec 192,445-1591,51492
30 Sep 192,355141,08115
30 Jun 192,727511,04218
31 Mar 192,5701211,03819
31 Dec 182,4721201,02619
30 Sep 182,6161401,11445
30 Jun 182,2141231,00043
31 Mar 182,0759374933
31 Dec 171,8258766131
30 Sep 171,7531726024
30 Jun 171,5111645720
31 Mar 171,5411725770
31 Dec 161,5091655540
30 Sep 161,4571324240
30 Jun 161,5941964230
31 Mar 161,6491974280
31 Dec 151,6441954230
30 Sep 151,4842263590
30 Jun 151,4281823630
31 Mar 151,3711783520
31 Dec 141,3431633310
30 Sep 141,2641783220
30 Jun 141,1851293170
31 Mar 141,018963150
31 Dec 131,018943080

Kwaliteitswinsten: 000566 is currently unprofitable.

Groeiende winstmarge: 000566 is currently unprofitable.


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: 000566 is unprofitable, but has reduced losses over the past 5 years at a rate of 8.1% per year.

Versnelling van de groei: Unable to compare 000566's earnings growth over the past year to its 5-year average as it is currently unprofitable

Winst versus industrie: 000566 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-1.2%).


Rendement op eigen vermogen

Hoge ROE: 000566 has a negative Return on Equity (-20.61%), as it is currently unprofitable.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden